Accelerating Next-Generation Vaccine Development for Global Disease Prevention
Open accessAbstract
Building Better Vaccines: Vaccines are one of the most effective tools to protect against infectious diseases. Unfortunately, vaccines for diseases with the highest global health burdens, such as HIV, malaria, and tuberculosis, are not yet available. Koff et al. ( 1232910 ) review the latest advances in vaccine development and why these particular diseases remain such a challenge. Respiratory syncytial virus (RSV) is a serious cause of morbidity and mortality in infants and young children worldwide. Although a prophylactic antibody is available for children at high risk, a vaccine is much needed. As a potential step toward this goal, McLellan et al. (p. 1113 , published online 25 April) solved the cocrystal structure of a neutralizing antibody (D25) bound to the prefusion F protein of RSV. Knowledge of the structure of the prefusion protein should help to guide vaccine design and the development of additional therapeutics.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Vaccines based on mRNA offer multifaceted advantages including flexible antigen design, a cost-effective manufacturing process allowing for parallel production of multiple mRNA vaccines, and rapid manufacturing.
“Vaccines based on mRNA could meet these requirements because they offer multifaceted advantages including flexible antigen design, a cost-effective manufacturing process allowing for parallel production of multiple mRNA vaccines1–5 and rapid manufacturing, which could be of crucial importance during pandemics.6”
From Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines (2017) · cites this paper as [6]
The Introduction and Antigen Discovery Technologies sections discuss advances in vaccine design generally, but do not address the claimed advantages of mRNA vaccines. Searches for mRNA, manufacturing, and parallel production found no passage in our copy that substantiates those advantages; the citing sentence assigns rapid manufacturing to a separate citation. (LLM, conf=0.75)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 86 · Cited by 282
Research works printed but not linked: 3
- [15]Miller MA Hinman AR Plotkin SA Orenstein WA Offit PA Vaccines 2008 1594 1610 Saunders Philadelphia
- [20]Siegrist C-A Vaccines 2013 14 32 W.B. Saunders London Sixth Edition
- [29]Daum RS Vaccines 2013 1161 1168 W.B. Saunders London Sixth Edition
- Authors
- Koff, W. C., Burton, D. R., Johnson, P. R., Walker, B. D., King, C. R., Nabel, G. J., Ahmed, R., Bhan, M. K., & Plotkin, S. A.
- Affiliations
- International AIDS Vaccine Initiative (US)
- Scripps Research Institute (US)
- Children's Hospital of Philadelphia (US)
- Sanofi-Aventis, 270 Albany Street, Cambridge, MA 02139, USA.
- Government of India (IN)
- University of Pennsylvania (US)
- Corresponding author
- Koff, Wayne C.
- ORCID
- Venue
- Science
- Published
- 2013-05-31
- Volume
- 340
- Issue
- 6136
- Pages
- 1232910-1232910
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4026248
- OpenAlex
- W2046498003
- Cited by
- 282
- References
- 86
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 18 · 2023: 16 · 2022: 13 · 2021: 22 · 2020: 25 · 2019: 17 · 2018: 12 · 2017: 26 · 2016: 18 · 2015: 40 · 2014: 49 · 2013: 4
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (UM1AI100663)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- vaccine development, vaccine discovery, correlates of protection, immune evasion, genetic variation, AIDS, tuberculosis, malaria, vaccinology, vaccine-induced immune response, human immunology
- MeSH terms
- Acquired Immunodeficiency Syndrome, Adjuvants, Immunologic, Animals, Antigens, Communicable Disease Control, Disease Models, Animal, Humans, Malaria, Tuberculosis, Vaccines, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
